PROteolysis-TArgeting Chimeras (PROTACs) are a revolutionary targeted protein degradation strategy. To date, several PROTACs that degrade leukemic oncoproteins have successfully overcome many of the limitations of conventional therapies. Although recent, the already enormous potential presented by PROTACs has aroused growing global interest, both from academia and industry, which could translate, sooner or later, into their reaching the pharmaceutical market.
https://www.pharmafocusamerica.com/articles/protacs-in-leukemia-a-novel-drug-discovery-strategy-from-lab-bench-to-the-pharmaceutical-market
PROTACs in Leukemia: A Novel Drug Discovery Strategy from Lab Bench to the Pharmaceutical Market